TY - JOUR
T1 - Open-Angle Glaucoma
T2 - Burden of Illness, Current Therapies, and the Management of Nocturnal IOP Variation
AU - Sheybani, Arsham
AU - Scott, Rachel
AU - Samuelson, Thomas W.
AU - Kahook, Malik Y.
AU - Bettis, Daniel I.
AU - Ahmed, Iqbal Ike K.
AU - Stephens, J. David
AU - Kent, Delaney
AU - Ferguson, Tanner J.
AU - Herndon, Leon W.
N1 - Funding Information:
This study has no formal funding or sponsorship. The Rapid Service Fees were funded by Tanner J. Ferguson, MD, the corresponding author. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Dr. Arsham Sheybani is a consultant for Allergan. Dr. Thomas Samuelson is a consultant for Ivantis, Alcon Surgical, MicroOptix, Santen, and Allergan. Dr. Malik Kahook is a consultant for Allergan, Alcon, and New World Medical. Dr. Ike Ahmed is a consultant for the following: Aquues, Aerie Pharmaceuticals, Alcon, Allergan, ArcSCan, Bausch & Lomb, Beaver Visitec, Camras Vision, Carl Zeiss Meditec, CorNeat Vision, Ellex, Elutimed, Equinox, Genentech, Glaukos, Gore, Iantech, InjectSense, Iridex, iStar Medical, Ivantis, Johnson & Johnson Vision, KeloTec, Layer Bio, Leica Microsystem, MicroOptx, New World Medical, Omega Ophthalmics, Polyactivia, Sanoculis, Santen, Science Based Health, Sight Sciences, Stroma, True Vision, Vizzario, Akorn, Beyeonics, ELT Sight, MST Surgical, Ocular Instruments, Ocular Therapeutics, and Vialase. Dr. Tanner J. Ferguson is a consultant for Glaukos, Equinox. Drs. Daniel Bettis, Rachel Scott, Delaney Kent, J. David Stephens, and Leon Herndon have no relevant financial disclosures. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Publisher Copyright:
© 2019, The Author(s).
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Glaucoma is a chronic, debilitating disease and a leading cause of global blindness. Despite treatment efforts, 10% of patients demonstrate loss of vision. In the US, > 80% of glaucoma cases are classified as open-angle glaucoma (OAG), with primary open-angle (POAG) being the most common. Although there has been tremendous innovation in the surgical treatment of glaucoma as of late, two clinical variants of OAG, normal-tension glaucoma (NTG) and severe POAG, are especially challenging for providers because patients with access to care and excellent treatment options may progress despite achieving a “target” intraocular pressure value. Additionally, recent research has highlighted the importance of nocturnal IOP control in avoiding glaucomatous disease progression. There remains an unmet need for new treatment options that can effectively treat NTG and severe POAG patients, irrespective of baseline IOP, while overcoming adherence limitations of current pharmacotherapies, demonstrating a robust safety profile, and more effectively controlling nocturnal IOP. Funding The Rapid Service Fees were funded by the corresponding author, Tanner J. Ferguson, MD.
AB - Glaucoma is a chronic, debilitating disease and a leading cause of global blindness. Despite treatment efforts, 10% of patients demonstrate loss of vision. In the US, > 80% of glaucoma cases are classified as open-angle glaucoma (OAG), with primary open-angle (POAG) being the most common. Although there has been tremendous innovation in the surgical treatment of glaucoma as of late, two clinical variants of OAG, normal-tension glaucoma (NTG) and severe POAG, are especially challenging for providers because patients with access to care and excellent treatment options may progress despite achieving a “target” intraocular pressure value. Additionally, recent research has highlighted the importance of nocturnal IOP control in avoiding glaucomatous disease progression. There remains an unmet need for new treatment options that can effectively treat NTG and severe POAG patients, irrespective of baseline IOP, while overcoming adherence limitations of current pharmacotherapies, demonstrating a robust safety profile, and more effectively controlling nocturnal IOP. Funding The Rapid Service Fees were funded by the corresponding author, Tanner J. Ferguson, MD.
KW - Glaucoma treatment
KW - Normal-tension glaucoma
KW - OAG
KW - Open-angle glaucoma
KW - Pharmacotherapy
KW - Surgical treatment of glaucoma
UR - http://www.scopus.com/inward/record.url?scp=85081005999&partnerID=8YFLogxK
U2 - 10.1007/s40123-019-00222-z
DO - 10.1007/s40123-019-00222-z
M3 - Comment/debate
C2 - 31732872
AN - SCOPUS:85081005999
SN - 2193-8245
VL - 9
JO - Ophthalmology and Therapy
JF - Ophthalmology and Therapy
IS - 1
ER -